Skip to content
Screener

Omeros OMER Total Equity

Total Equity at other companies

Immunome logo
ImmunomeIMNM
$588.69M+91.7%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$408.73M-30.8%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$576.22M+4,094%
Annexon logo
AnnexonANNX
$204.53M-16.1%
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
$302.07M+152%
Vor Biopharma logo
Vor BiopharmaVOR
-$150.42M-328%

Other financials

Income statement

See full
Revenue$9.9M
Gross profit$29.7M
Operating income-$40.9M-9.2%
Net income$56.1M+268%
EPS (diluted)-$0.59-20.4%

Balance sheet

See full
Cash & equivalents$1.9M-55.3%
Total debt$13.5M-30.3%
Total assets$286.2M+21.7%

Cash flow

See full
Operating cash flow-$14.5M+59.5%
CapEx--100%
Free cash flow-$14.5M+59.6%

Valuation

See full
Market cap$958.97M+245%
P/S10.7×

Profitability

See full
Gross margin98.9%
Operating margin-181.8%
Net margin-136.6%
FCF margin-121.6%

Returns & leverage

See full
Return on equity86.6%
Debt / equity0.3×-1.1×
Current ratio+1.9×

Where this comes from

Reported directly by Omeros in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The source filing: Omeros’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 4:07 PM EDT
Fiscal quarter
Q4 FY2026
Calendar quarter
Q4 2026
Accession
0001437749-26-016720
Line itemMarch 31, 2026December 31, 2025
Commitments and contingencies (Note 10)
Shareholders’ deficit:
Preferred stock, par value $0.01 per share, 20,000,000 shares authorized; none issued and outstanding at March 31, 2026 and December 31, 2025.
Common stock, par value $0.01 per share, 150,000,000 shares authorized at March 31, 2026 and December 31, 2025; 71,998,632 and 71,670,791 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively.720716
Additional paid-in capital793,581791,748
Accumulated deficit(857,635)(913,695)
Total shareholders’ deficit(63,334)(121,231)
Total liabilities and shareholders’ deficit$286,173$325,632

Document

FAQ

What is Omeros's total equity?
Omeros (OMER) reported total equity of -$63.33M in Q1 2026.
How has Omeros's total equity changed year-over-year?
Omeros's total equity increased by 70.3% year-over-year, from -$213.55M to -$63.33M.
What is the long-term trend for Omeros's total equity?
Over 5 years (2020 to 2025), Omeros's total equity has grown at a 0.1% compound annual growth rate (CAGR), from -$120.75M to -$121.23M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.

Ask your AI about Omeros's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude